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Background: Rabies is a fatal zoonotic neglected disease that occurs in more than 150 countries, and kills more than
55.000 people every year. It is caused by an enveloped single stranded RNA virus that affects the central nervous system,
through an infection initiated by the muscular nicotinic acetylcholine receptor, according to many authors. Alkaloids, such
as acetylcholine, are widespread molecules in nature. They are present in numerous biological fluids, including the skin
secretion of many amphibians, in which they act (together with proteins, peptides and steroids) as protection agents
against predators and/or microorganisms. Among those amphibians that are rich in alkaloids, there is the genus Rhinella.
Methods: Bufotenine was isolated from Rhinela jimi skin secretion after a liquid-liquid partition (H2O:CH2Cl2) and reversed
phase high-performance liquid chromatography analyses (RP-HPLC). Bufotenine was also extracted from seeds of
Anadenanthera colubrina in acetone solution and purified by RP-HPLC, as well. Structural characterization was performed
by mass spectrometry and nuclear magnetic resonance analyses. Cytotoxic tests of bufotenine were performed over
baby hamster kidney (BHK-21) cells using MTT test. For the antiviral activity, Rabies virus strain Pasteur vaccine (PV) was
used on fluorescence inhibition test and fluorescent foci inhibition test, with both simultaneous and time course
treatment of the cells with the virus and bufotenine.
Results: In the present work we describe the effects of bufotenine, obtained either from toads or plants, that can
inhibit the penetration of rabies virus in mammalian cells through an apparent competitive mechanism by the
nicotinic acetylcholine receptor. Moreover, this inhibition was dose- and time-dependent, pointing out to a specific
mechanism of action.
Conclusions: This work do not present or propose bufotenine as a drug for the treatment of rabies due to the
hallucinogen and psychotropic effects of the molecule. However, continued studies in the elucidation of the
antiviral mechanism of this molecule, may lead to the choice or development of a tryptamine analogue presenting
potential clinical use.
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According to the World Health Organization (WHO), ra-
bies is a zoonotic neglected disease that occurs in more
than 150 countries and territories, killing more than
55,000 people every year, mostly in Asia and Africa [1].
It is caused by a virus that affects the central nervous
system and, once symptoms have developed, is nearly
always fatal [2,3]. Different in vitro experiments showed* Correspondence: dcpimenta@butantan.gov.br
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unless otherwise stated.evidences that some cells receptors, such as the muscular
form of the nicotinic acetylcholine receptor (nAChR), are
capable of participating on the entry of rabies virus into
cells [4-7]. Other molecules – including the p75 neutro-
phin, the neuronal cell adhesion molecule (NCAM) and
glicosides of the cell membrane – are also capable of par-
ticipating in the entry of rabies virus into cells, maybe
involved in different stages of the infection [8]. Con-
formational studies on an internal tetrapeptide of rabies
virus glycoprotein (Asn194-Ser195-Arg196-Gly197) consid-
ered this to be an essential part of the binding site of the
virus to the acetylcholine receptor and have demonstratedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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parently, mimic the acetylcholine spatial structure, be-
ing responsible for binding the virus to the acetylcholine
receptor [9].
The skin secretion of some amphibians, on the other
hand, is rich in alkaloids [10]. Not only that, but also pro-
teins, peptides, steroids and amines that act as chemical
protection agents against predators and/or microorganisms,
such as fungi and bacteria [8,11]. Among those amphibians
that are rich in alkaloids, there is the genus Bufo that
was recently split into Bufo in the Old World and Rhinella
in the New World [12]. Their secretion contain a large
number of alkaloids including bufotenine – a tryptamine
alkaloid used as a defense mechanism due to its toxicity –
that is also found in the Leguminosae family [13-16].
Taking into account that the rabies virus can bind to the
nicotinic acetylcholine receptor, and that other alkaloids
(nicotine, lobeline, cytisine, anabasine etc.) can also bind
to these receptors, the aim of this study was to evaluate
the effects of bufotenine as a possible interfering agent in
the process of infection of the rabies virus in mamma-
lian cells, using the simplified fluorescent inhibition microt-
est (SFIMT) and rapid fluorescent focus inhibition test
(RFFIT) techniques (with adaptations). Both are sero-
logic tests commonly used in rabies diagnosis that are
considered viable tools for the evaluation of new natural
compounds as potential antiviral agents.
Methods
Reagents
All reagents were of analytical grade and were purchased
from Sigma Aldrich (USA), unless otherwise stated.
Isolation of bufotenine from Rhinella jimi skin secretion
The collection and housing of Rhinella jimi specimens
were performed under license number 15964-1 from the
Brazilian Institute of Environment and Renewable Natural
Resources (IBAMA). Skins secretions were collected through
mechanical stimulation of the parotoid macroglands. A
liquid-liquid partition (H2O:CH2Cl2) was performed and the
aqueous partition was centrifuged at 4,794 g and the super-
natant was analyzed by reversed phase high-performance
liquid chromatography (RP-HPLC), using a binary HPLC
system (20A Prominence, Shimadzu Co, Japan), coupled to
a C18 column (ACE®, 250 mm× 7.75 mm). The mobile
phase consisted of solvent A [H2O: trifluoroacetic acid
(TFA); 1000:1] and solvent B [acetonitrile (ACN):H2O:TFA;
900:100:1] with a linear gradient of B over A (10% to 70%)
in 35 minutes, at a constant flow rate of 1.7 mL.min-1 and
monitored by UV absorbance at 214 nm. Fractions were
manually collected and submitted to mass spectrometry
(MS and MS2 ESI-IT-TOF) analyses. The fraction contain-
ing bufotenine was then purified using a C18 column
(ACE®, 250 mm × 4.6 mm), with a linear gradient of Bover A 13% to 15% in 15 minutes, at a constant flow rate
of 1.1 mL.min-1, at 4°C, monitored by UV absorbance at
214 nm. Bufotenine peak was manually collected, dried
and submitted to 1H-NMR spectroscopic analyses and/or
biologic assays.
Isolation of bufotenine from Anadenanthera colubrine
seeds
Since bufotenine is a long and well known alkaloid that
can be also obtained from other biological sources,
such as plants, we chose to purify this molecule from
Anadenanthera colubrina seeds, which contain up to 2%
of the seed dry weight in bufotenine. The seeds were ob-
tained from the legitimate supplier Arbocenter Comércio
de Sementes Ltda, Birigui, São Paulo (batch 0019), Brazil.
The extraction of bufotenine was performed as described
by Stromberg [16], with modifications. Twenty grams of
seeds were powdered and subsequently deionized H2O and
5 g of sodium carbonate (Na2CO3) were added until a uni-
form mixture was obtained. This solution was then lyophi-
lized and ressuspended in 50 mL of acetone (CH3COCH3).
This extract was filtered and concentrated in a rotavapor
system, following RP-HPLC analysis, in a C18 column
(ACE®, 250 mm × 4.6 mm), with a linear gradient of B
over A 0% to 100% in 20 minutes, at a constant flow rate
of 1 mL/min and monitored by UV absorbance at 214 nm.
Bufotenine peak was manually collected and dried for mass
spectrometry and biologic assays.
Mass spectrometry
Previously dried samples were dissolved into 50% ACN
with 0.5% formic acid for MS and/or MS2 analyses in an
ESI-IT-TOF mass spectrometer system (Shimadzu Co.,
Japan). Typically, 3 μL of samples were manually injected
in a Rheodyne injector under a constant flow of 50 μL/min.
The interface voltage used was 4.5 kV and detector voltage,
1.76 kV, with source temperature of 200°C. Data were ac-
quired under positive mode and instrument control, data
acquisition and processing were performed by the LCMS
solution software (Shimadzu Co., Japan).
NMR analyses
NMR screening was used to confirm the bufotenine struc-
ture from Rhinella jimi skin secretion. 1H NMR spectra
were recorded on Bruker 500 MHz spectrometer (Bruker
Co., Germany), with samples diluted in deuterated chloro-
form and achievement of 128 scans. The results were proc-
essed in TopSpin 1.3 software (Bruker Co., Germany).
Cells and viruses
Baby hamster kidney (BHK-21) cells (ATCC® CCL – 100)
were cultured in Eagle’s minimum essential medium, sup-
plemented with 10% fetal bovine serum (MEM-10), at 37°C
under a humidified 5% CO2 atmosphere until the formation
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cine (PV), from Pasteur Institute, Brazil, was used to deter-
mine the antiviral activity of bufotenine. The titers
were determined by plate assay in BHK-21 cells and
expressed as 100% infecting dose in cell culture (IDCC100)
and 50% focus-forming dose (FFD50) as described by
Batista et al. [17].
Cytotoxicity assay
The cytotoxicity evaluation of bufotenine was performed
by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide] method, according to Takeuchi et al. [18]
and Mosmann [19], with modifications. Briefly, BHK-21
cells (5 × 104 cells/well) were deposited in 96-well tissue
culture microtiter plates with 50 μL of different bufote-
nine concentrations diluted in MEM-10. For positive con-
trol of citotoxicity dimethyl sulfoxid (DMSO) 20% was used
and the negative control was MEM-10 alone. After 24
hours at 37°C, under a humidified 5% CO2 atmosphere, the
medium was removed and 50 μL of MTT (Sigma® 1 mg/
mL) solution, prepared in MEM-10, was added to each well
and the plates were incubated once more for four hours.
After incubation, the MTT solution was removed and 100
μL of dimethyl sulfoxide (DMSO) were added to each well
to solubilize the formazan crystals. After gently shaking the
plates, the crystals were completely dissolved, and the
absorbances were measured by using a spectrophotom-
eter (Molecular Devices®, SpectraMax M2) at 540 nm.
The CC50 was defined as the cytotoxic concentration of
bufotenine that reduced the absorbance of treated cells to
50% when compared to the control.
Antiviral activity
Rabies virus does not cause cytopathic effects in cells cul-
tured in vitro, being necessary some kind of additional test
to monitor cell infection, such as tests with antibodies
bound to fluorescent substances [20]. For this reason,
we choose these two tests adapted from commonly sero-
logical tests used for antirabies virus titration, being the
fluorescence inhibition a qualitative test, for a better visua-
lization of both the infection and its inhibition, and the
fluorescence focus inhibition comprises a quantitative test,
used for the statistical analyses.
Fluorescence inhibition test
This test was based on simplified fluorescent inhibition
microtest (SFIMT), acording to Favoretto et al. [21], with
modifications. Briefly, 50 μL of BHK-21 cells (5 × 104 cells/
well) were deposited on 96-well tissue culture microtiter
plates with 50 μL of each bufotenine dose (from 0.5 to 4
mg/mL) and 50 μL of PV virus previously diluted at 1:100
(IDCC100). As negative inhibition control, only 50 μL of
MEM-10 was added to the cells and as positive inhibition
control ketamine was used (Dopalen®, 23.4 μM), accordingto Lockhart et al. [22]. After a 24-hour period of incuba-
tion at 37°C under a humidified 5% CO2 atmosphere, the
medium was removed by suction from all wells and the
microplates were cooled on ice. The cells were fixed by
adding acetone 80% in water (kept at –20°C). After 15
minutes, the plates were emptied by inversion and dried at
37°C according to Smith et al. [23] and Chaves et al. [24].
The staining was carried out by adding 40 μL of an optimal
dilution of the antirabies fluorescent conjugate [25]. After
one hour of incubation, the microtiter plates were washed
by immersion in PBS and then in distilled water. The
microtiter plates reading was performed in inverted fluor-
escence microscope (Leica DMIL, 100× magnification) in
a qualitative manner based on the fluorescence inhibition
compared to negative and positive controls, where there
are 100% and 0% of fluorescence, respectively.Fluorescent focus inhibition test
This test was based on rapid fluorescent focus inhibition
test (RFFIT) acording to Smith et al. [23], adapted to mi-
crotiter plates as described by Chaves et al. [24], with mod-
ifications. Briefly, 100 μL of BHK-21 cells (2.5 × 104 cells/
well) were deposited on 96-well tissue culture microtiter
plates containing different bufotenine doses (3.9, 1.95, 0.97
and 0.48 mg/mL), and 50 μL of PV virus previously diluted
at thirty-fold the FFD50 value. As negative inhibition con-
trol, only 50 μL of MEM-10 was added to the cells and as
positive inhibition control ketamine was used (Dopalen®,
23.4 μM). After a 20-hour period of incubation at 37°C
under a humidified 5% CO2 atmosphere, the medium was
removed by suction from all wells. The procedures of cells
fixation and staining were the same described in “Fluores-
cence inhibition test” section. The microtiter plates reading
was quantitatively performed in inverted fluorescence
microscope (Leica DMIL, 200× magnification), where each
field with fluorescence were counted, being 0 the mini-
mum (positive control) and 18 the maximum (negative
control) number of infected fields. The IC50 was de-
fined as the inhibition concentration of bufotenine that
reduced the number of fields with fluorescent foci to 50%
when compared with the negative control.Time course study
The time course effect of bufotenine was examined on
PV virus with two minor modifications of the fluorescent
focus inhibition test. First, to test a possible “protector
effect”, bufotenine was added in different times (1, 3 and
6 hours), prior to the addition of the virus and, secondly,
to test a possible “treatment effect”, bufotenine was added
in different times (1, 3 and 6 hours), after incubation of
cells and PV virus. All the other procedures were the same
as described in “Fluorescent focus inhibition test” section.
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The 50% cytotoxic (CC50) and inhibition (IC50) concentra-
tions were calculated from concentration-effect curves after
linear regression analysis. The results represent the mean ±
standard error of the mean values of two different experi-
ments (triplicates).Results
RP-HPLC and mass spectrometry analysis
RP-HPLC analysis of the aqueous partition of Rhinela jimi
skin secretion showed the presence of five major HPLC
peaks (Figure 1A). MS analysis showed that fraction 3
contained the following m/z values: 205, 219 and 160
(Figure 1B). Comparing the MS2 analysis with already
published data by McClean et al. [26] (Figure 1C), it was
possible to characterize the two indole alkaloids contained
in this fraction: the 205 m/z correspond to N’,N’-dimethyl
5-hydroxytryptamione (bufotenine) and 219 m/z corres-
pond to N’,N’,N’-trimethyl 5-hydroxytryptamine (5-HTQ).
The 160 m/z ion is a spontaneous fragmentation of both
alkaloids, which also appears on MS2 profile (Additional
file 1: Figure S1). This two compounds were separated by
RP-HPLC yielding pure bufotenine (Additional file 2:
Figure S2), as confirmed by NMR analyses (AdditionalFigure 1 RP-HPLC analysis of the aqueous partition of Rhinela jimi ski
(λ = 214 nm), showing five fractions. (B) MS analysis of fraction 3 showing
indole alkaloids bufotenine (205 m/z) and 5-HTQ (219 m/z), resulting in anfile 3: Figure S3). Bufotenine from Anadenanthera colubrina
seeds were purified only after one chromatographic step, fol-
lowing the acetone extract, being the major peak on the RP-
HPLC chromatogram and appearing pure on mass spectro-
metric analyses (Additional file 4: Figure S4).Cytotoxicity effect on viability of BHK-21 cells
The 3.9 mg/mL dose of R. jimi bufotenine used on the
virologic tests presented statistically significant cytotoxic
effects on the viability of BHK-21 cells (66% of viable cells)
when compared to the negative (cells +MEM-10) and
positive controls (cells + DMSO 20%) (Additional file 5:
Figure S5). Subsequent assays were performed with the
seeds bufotenine, due to the high availability. In the MTT
test (Additional file 6: Figure S6), it was possible to deter-
mine the CC50 value (7.6 mg/mL).
Antiviral activity
 Fluorescence inhibition test
Bufotenine was able to inhibit the infection significantly,
showing dose-response effect when tested at a concentra-
tion of 0.5 to 3 mg/mL (Figure 2).n secretion. (A) RP-HPLC profile of Rhinella jimi aqueous partition
three major molecules of 205, 219 and 160 m/z. (C) Fragmentation of
ion of 160 m/z.
Figure 2 Effects of bufotenine from Anadenanthera colubrine on fluorescence inhibition test. (A) positive inhibition control (ketamine);
(B) negative control (cells + MEM-10); bufotenine concentrations: (C) 0.5 mg/mL, (D) 1.0 mg/mL, (E) 1.5 mg/mL, (F) 2.0 mg/mL, (G) 2.5 mg/mL,
(H) 3.0 mg/mL. Magnification 100×. Insert magnification 200 ×.
Vigerelli et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2014, 20:45 Page 5 of 8
http://www.jvat.org/content/20/1/45 Fluorescent focus inhibition test
Bufotenine was able to inhibit 100% of the infection at
3.9 mg.mL-1. It was also possible to observe the dose-
response effect. Moreover, there was a time course de-
pendency of the effect regarding the moment of PV virus
administration, being bufotenine most effective when added
along with the cells and PV virus (time 0, Figure 3).On the other hand, when bufotenine was administered
over the time, the molecule was unable to inhibit the
infection, regardless of the tested concentration, from
one hour onwards (Figure 4). After testing different
bufotenine concentrations in the most effective condi-
tions used in the time course study (time 0), it was
possible to determine the IC50 value of (1.57 ± 0.03)
mg.mL-1 (Figure 5).


























Figure 3 PV virus inhibition effect of bufotenine on fluorescent
focus inhibition test, at different times adding PV virus (0, 1, 3
and 6 hours), compared with negative (cells +MEM-10) and
positive (ketamine) controls (black and white columns, respectively).
Bufotenine concentrations: 3.9 mg/mL (gray columns), 1.95 mg/mL
(checkered columns), 0.97 mg/mL (striped columns) and 0.48 mg/mL
(diagonally striped columns).





















Figure 5 PV virus inhibition percentage of different bufotenine
concentrations on fluorescent focus inhibition test compared
with negative (cells + MEM-10) and positive (ketamine) controls.
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Although bufotenine was isolated “only” in 1920, shamans
and mystics have been employing toads’ skin secretions
since ancient times as entheogens, which means “generating
the divine within” [27]. The chemical structure elucida-
tion was published in 1934 by the group of the chemist
Heinrich Otto Wieland and one can observe that the
molecule is related to psilocin and dimethyltryptamine
(DMT), which are known hallucinogens, as well to the
neurotransmitter serotonin [28]. Another early report on


























Figure 4 PV virus inhibition effect of bufotenine added in
different times (0, 1, 3 and 6 hours) on fluorescent focus
inhibition test, compared with negative (cells +MEM-10) and
positive x (ketamine) controls (black and white columns,
respectively). Bufotenine concentrations: 3.9 mg/mL (gray columns),
1.95 mg/mL (checkered columns), 0.97 mg/mL (striped columns) and
0.48 mg/mL (diagonally striped columns).roman poet Decimus Junius Juvenalis (60-128 AD) in the
first century.
In this work, we describe bufotenine as an inhibitor of
rabies virus penetration in mammal cells. Initial bufotenine
isolation and characterization was performed from the skin
secretion of the toad R. jimi based on biological effect-
driven assays, as previously done by the authors [13,29-31].
After initial molecular identification and characterization,
we have opted for obtaining this molecule from a more
abundant source, so the seeds of Anadenanthera colubrina
were chosen, according to early reports on the isolation of
this alkaloid of Anadenanthera genus [16].
Bufotenine has been purified, described and synthesized
many years ago [32-34]. However, the original isolation
process includes several steps of extraction, filtering, parti-
tioning and pH adjustments [16]. In our work, on the other
hand, we were able to demonstrate that the use of chroma-
tographic techniques allows for greater efficiency in the
purification of this molecule. Moreover, the association
with mass spectrometry analyses allow further evaluation
of the purity degree, as well as molecular identity confirm-
ation, for the subsequent biological assays. From the toad
skin secretion, pure bufotenine could be obtained after
two chromatographic steps, and from the seeds, bufote-
nine was purified after acetone extraction employing only
one chromatographic step, which increased the efficiency
and the yield in the obtainment of the pure molecule.
There are recent described effects of hydroalcoholic
extracts of different parts of A. colubrina, such as anti-
inflammatory and peripheral antinociceptive activities in
rodent models, antimicrobial (anti-Staphylococcus) and
cutaneous wound healing in rats, among others [35-37].
However, these reports describe biological effects of extracts
rather than pure molecules. Although the toxic and halluci-
nogens effects of bufotenine are widely discussed and stud-
ied, no reports about its antiviral activity are known to the
best of our knowledge [38-40].
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virus penetration known (or postulated), the bufotenine
inhibition of rabies virus infection observed in this study
appears to be related to the competition to the cells’ re-
ceptors, since it could only be observed when simultaneous
administration of bufotenine and PV virus was performed
(Figure 4). However, the elucidation of this mechanism
depends on electrophysiological and/or patch clamp ex-
periments to be performed in the future.
Numerous authors have described that there are high-
affinity receptors at host cells specific for rabies virus, which
include AChR – and/or associated molecules – that act
as receptors. Although it was not possible to unequivocally
demonstrate that the inhibitory effect of bufotenine was
mediated by its binding to the acetylcholine receptor, the
results of this work open important perspectives in the
study of the mechanism of action of bufotenine, as well as
the elucidation of the mechanisms of the virus pathogen-
icity. Altogether, our data may aid in the development
of 2nd generation active molecules, since rabies is still a
disease with no cure prognosis and it kills, every year,
thousands of people around the world [1]. Furthermore,
bufotenine is cytotoxic, so medicinal chemistry and lead
optimization will be required.
Conclusions
This work do not present or propose bufotenine as a drug
for the treatment of rabies for several reasons, including
the hallucinogen and psychotropic effects of the molecule.
However, continued studies in the elucidation of the anti-
viral mechanism of this molecule may lead to the choice
or development of a tryptamine analogue presenting
potential clinical use. These tryptophan derived alka-
loids are very interesting building blocks in organic
chemistry syntheses [41]. Our next goal would be to
evaluate such analogues as possible inhibitors of the
viral infection, targeting the dissociation of toxic and
psychotropic effects from the antiviral effect.
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